PT  - JOURNAL ARTICLE
AU  - Reynolds, Sandra R.
AU  - Celis, Esteban
AU  - Sette, Alessandro
AU  - Oratz, Ruth
AU  - Shapiro, Richard L.
AU  - Johnston, Dean
AU  - Fotino, Marilena
AU  - Bystryn, Jean-Claude
TI  - HLA-Independent Heterogeneity of CD8<sup>+</sup> T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients
DP  - 1998 Dec 15
TA  - The Journal of Immunology
PG  - 6970--6976
VI  - 161
IP  - 12
4099  - http://www.jimmunol.org/content/161/12/6970.short
4100  - http://www.jimmunol.org/content/161/12/6970.full
SO  - J. Immunol.1998 Dec 15; 161
AB  - An important element in melanoma vaccine construction is to identify peptides from melanoma-associated Ags that have immunogenic potential in humans and are recognized by CD8+ T cells in vivo. To identify such peptides, we evaluated HLA-A*02+ melanoma patients immunized to a polyvalent vaccine containing multiple Ags, including MAGE-3, Melan-A/MART-1, gp100, tyrosinase, melanocortin receptor (MC1R), and dopachrome tautomerase (TRP-2). Using a filter spot assay, we measured peripheral blood CD8+ T cell responses, before and after immunization, to a panel of 45 HLA-A*0201-restricted peptides derived from these Ags. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLA-A*0201. Vaccine treatment induced peptide-specific CD8+ T cell responses to 22 (47.8%) of the peptides. The most striking finding was the HLA-independent heterogeneity of responses to both peptides and Ags. All responding patients reacted to different combination of peptides and Ags even though the responding patients were all A*0201+ and the peptides were all A*0201-restricted. From 9 to 27% of patients developed a CD8+ T cell response to at least one peptide from each Ag, but no more than 3 (14%) reacted to the same peptide from the same Ag. This heterogeneity of responses to individual peptides and Ags in patients with the same haplotype points to the need to construct vaccines of multiple peptides or Ags to maximize the proportion of responding patients.